Volume 5 Supplement 6
The emergence of carbapenem resistance in ESBL-producing Escherirchia coli O25B-ST131 strain from community acquired infection in Kuwait
© Dashti et al; licensee BioMed Central Ltd. 2011
Published: 29 June 2011
Introduction / objectives
In this study we investigated a multi-drug resistant E.coli recovered from ascetic fluid of a haemodialysis patient with community-onset urinary tract infection from Al-Amiri hospital in Kuwait. The patient was suffering from advanced liver disease with portal hypertension and multiple current inter abdominal abscesses.
Antimicrobial susceptibility was determined by Vitek2, Microscan, disc diffusion, E-test & double disc method against antibiotics. PCR& sequencing were performed forO25pabBspe, pabB, trpA, chuA, yjaA TSPE4, blaSHV, blaTEM, blaCTX-M15, blaOXA-1-like, aac(6′)-Ib-cr, tet(A), tet(B), gyrA, parC, plasmid mediated qnrA, qnrB, qnrS, IMP, SPM, VIM, OXA-48, NDM, KPC and classes 1and 2 integrons.
The isolate was confirmed as E. coli O25b-sequence type (ST) 131 clone of B2 phylogenetic group. The isolate was resistant to all antibiotics tested except sulfamethoxazole, trimethoprim and nitrofurantoin and E-test confirmed that it is highly resistant to meropenem, imipenem, ciprofloxacin, cefotaxime and ceftazidime with MIC values of >16 mg/l, 32 mg/l, >64 mg/l, 32 mg/l & >32mg/l respectively. PCR detected the expected sizes of the amplified resistance genes, and DNA sequencing confirmed that TEM-1, the novel SHV-122 GeneBank (GQ290211), CTX-M-15, OXA-1, variant aac(6′)-Ib-cr, tet(A) genes, VIM and KPC were present and it was found to carry a class 1 integron. No mutation was found in gyrA but in ParC a mutation at 520 G to C, with amino acid change 174 Val (GTC) to Leu (CTC) was detected. QnrA, B, S and integron 2 were not present.
This is the first report of the emergence and the detection of a multiple antibiotic resistant E. coli O25b-sequence type (ST)131 containing 2 carbapenemase genes in Kuwait.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.